Evidence map›Paper›PMID 39472411›Full record

ArticleClinical rheumatology2024

Structured and prompt treatment of early arthritis in clinical practice leverages window of opportunity and leads to excellent clinical outcomes: an innovative retrospective cohort study.

R L Teixeira, R da Silva Vieira, M J Saavedra, J Polido-Pereira, R A Moura, I Alcobia, J E Fonseca, V C Romão

Abstract read
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

R L TeixeiraRheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal. rteixeira@edu.ulisboa.pt.ORCID http://orcid.org/0000-0001-7324-4522
R da Silva VieiraFaculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
M J SaavedraRheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
J Polido-PereiraRheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
R A MouraFaculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
I AlcobiaFaculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
J E FonsecaRheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.
V C RomãoRheumatology Department, Unidade Local de Saúde de Santa Maria, Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWith this work, we evaluated the impact of the Lisbon Early ARthritis cliNic (LEARN) on untreated inflammatory arthritis clinical and patient-reported outcomes.

methodsA retrospective cohort study enrolled patients in LEARN since its inception. Patients were followed for 12 months and treated to achieve disease remission. Clinical, structural, and quality of life outcomes were assessed. The early arthritis module of the Portuguese Rheumatic Diseases Registry (Reuma.pt) is described.

resultsWe assessed 292 patients between 2015 and 2022. Mean symptom duration and DAS-28-4 V-ESR at baseline were 6.2 ± 3.5 months and 5.6 ± 1.3, respectively. Rheumatoid arthritis (56.4%; 40.1% seropositive) and psoriatic arthritis (12.4%) were the most common diagnoses. Most patients were treated with methotrexate (75.3%) combined with low-dose oral prednisolone (88.1%). At 12 months, a mean ΔDAS28-4 V-ESR improvement of 2.3 ± 0.4 was registered, with 29.5% and 48.9% of patients achieving remission (DAS28-4 V-ESR < 2.6) or low disease activity (DAS28-4 V-ESR < 3.2), respectively. Among RA patients only, these figures were 20.6% and 46.6%, respectively. A clinically meaningful functional improvement was observed in 72.1% of the patients. Structural progression was limited, affecting only 16.1% of the patients. Fatigue, anxiety, depression, and quality of life also improved substantially, translated by improvements in FACIT, HADS, EQ5D, and SF-36 scores.

conclusionsA structured, dedicated approach to patients with early arthritis resulted in good clinical, structural, and functional outcomes. Furthermore, our findings suggest the window of opportunity for early intervention may have implications for mental health and global well-being. Key Points • Patient assessment is facilitated by reliable electronic clinical records, such as the early arthritis module of the Rheumatic Diseases Portuguese Register (Reuma.pt) which we describe here for the first time. • Inflammatory arthritis was confirmed in the majority of patients observed, but the time to first appointment was above the recommended. • Prompt start of conventional therapy allowed significant disease activity improvement and remission to be achieved in about one-third of the patients. • Key patient-reported outcomes elucidate disease impact and confirm the benefit of early treatment initiation, suggesting a window of opportunity also for mental health and global well-being.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidMethotrexatePrednisoloneQuality of LifeRemission InductionAdultAgedArthritis, PsoriaticFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresPortugalRetrospective StudiesAntirheumatic AgentsMethotrexatePrednisoloneArthritisQuality of lifeReferral and consultationRheumatic diseases

Identifiers

PMID39472411
PMCPMC11582134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.